Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05200390
Other study ID # 1788320
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date January 24, 2022
Est. completion date February 2023

Study information

Verified date May 2022
Source State University of New York - Upstate Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to hopefully generate interest that will lead to more robust trials evaluating FreeStyle Libre 2 sensors in patients with type 2 diabetes on any diabetes regimen. Hopefully the trial will ultimately pave the way to future trials that will prompt clinicians, policymakers, and insurers to re-evaluate the current criteria defining the coverage of continuous glucose monitors (CGM). The objectives of the study are to 1) Determine if there is difference in diabetes control in adult participants with type 2 diabetes before and after management with FreeStyle Libre 2, 2) Compare participant satisfaction with glucose monitoring and diabetes distress in adult participants with type 2 diabetes before and after management with FreeStyle Libre 2 and 3) Compare the frequency of hypoglycemia in adult participants with type 2 diabetes before and after management with FreeStyle Libre 2.


Description:

This will be a prospective, single-center, pre-post pilot study where enrolled participants will be given free FreeStyle Libre 2 sensors for 3 months and will be followed by pharmacists in the Upstate Adult Medicine Clinic. During the first visit, pharmacists will order a baseline hemoglobin A1c, confirm the participant's current medication list, provide CGM education and assess patient's willingness to scan. Participants will also be asked to participate in a voluntary initial satisfaction survey (Glucose Monitoring Satisfaction Survey). Sensors will be placed at the end of the first visit. No medication changes will be made in order to obtain baseline data for each participant. All initial visits will be conducted in-office. Baseline characteristics will be collected at this visit. The second visit will be scheduled approximately 2 weeks after the initial visit and will also be in-office. Since no medication changes were made during the first visit, the second visit will provide baseline CGM data, which will be reviewed with the participant. All subsequent follow-up visits will be scheduled at 2-week intervals unless an earlier visit is determined to be necessary by the pharmacist. At the discretion of the pharmacists, subsequent follow-up visits can either be a telemedicine encounter or an in-office visit. CGM data and medication changes will be documented at each visit. The final visit will be scheduled approximately 3 months after sensor placement and will be in-office. Participants will be asked to participate in the post satisfaction survey (Glucose Monitoring Satisfaction Survey). Pharmacists will repeat the hemoglobin A1c, review the final medication list, remove the sensors, and review plan for self-monitoring blood glucose with patient moving forward.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 15
Est. completion date February 2023
Est. primary completion date November 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of Type 2 Diabetes with 1. Hemoglobin A1c above goal 6.5%-8% based on participant specific factors defined in the ADA guidelines (e.g. comorbidities and age) OR 2. Identified glycemic excursions, including hypoglycemia based on documented blood glucose readings of < 70 mg/dL via point-of-care glucose testing, lab testing or self-monitoring or reported signs and symptoms of hypoglycemia documented in the medical record - Referred and actively followed by pharmacy for at least 3 months prior to study enrollment - Have at least one encounter with pharmacist within the last 3 months - Have at least one A1c documented while under pharmacist care - On at least one anti-diabetic medication - Demonstrates willingness (at the discretion of the investigators) to scan the CGM several times a day - Demonstrates willingness (at the discretion of the investigators) to attend regular office visits or phone calls Exclusion Criteria: - Currently pregnant or actively trying to conceive - Receiving dialysis - Currently followed by the endocrinology clinic for diabetes - Current or past CGM use in the last 6 months prior to study enrollment - Participant meets criteria for insurance coverage of CGM - Known allergy to medical adhesive - Wearing any implanted medical device

Study Design


Intervention

Device:
Continuous glucose monitor
FreeStyle Libre 2 system

Locations

Country Name City State
United States Upstate Health Care Center Syracuse New York

Sponsors (2)

Lead Sponsor Collaborator
Chieh Chen St. John Fisher College

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in percent time in range of 70-180mg/dL (%TIR) Percentage From baseline and at 3 months
Secondary Change in Glucose Monitoring Satisfaction Survey (GMSS) scores Numeric number From baseline and at 3 month
Secondary Change in %TIR Percentage From baseline and at 1 month
Secondary Change in %TIR Percentage From baseline and at 2 months
Secondary Change in hemoglobin A1c Percentage From baseline and at 3 months
Secondary Change in Percent Time Active Percentage From baseline and at 1 month
Secondary Change in Percent Time Active Percentage From baseline and at 2 months
Secondary Change in Percent Time Active Percentage From baseline and at 3 months
Secondary Change in Percent Time Below Range less than 54mg/dL (%TBR <54mg/dL) Percentage From baseline and at 1 month
Secondary Change in %TBR <54mg/dL Percentage From baseline and at 2 months
Secondary Change in %TBR <54mg/dL Percentage From baseline and at 3 months
Secondary Change in Percent Time Below Range less than 70mg/dL (%TBR <70mg/dL) Percentage From baseline and at 1 month
Secondary Change in %TBR <70mg/dL Percentage From baseline and at 2 months
Secondary Change in %TBR <70mg/dL Percentage From baseline and at 3 months
Secondary Change in Percent Time Above Range more than 180mg/dL (%TAR >180mg/dL) Percentage From baseline and at 1 month
Secondary Change in %TAR >180mg/dL Percentage From baseline and at 2 months
Secondary Change in %TAR >180mg/dL Percentage From baseline and at 3 months
Secondary Change in Percent Time Above Range more than 250mg/dL (%TAR >250mg/dL) Percentage From baseline and at 1 month
Secondary Change in %TAR >250mg/dL Percentage From baseline and at 2 months
Secondary Change in %TAR >250mg/dL Percentage From baseline and at 3 months
Secondary Change in Percent Coefficient of Variation (%CV) Percentage From baseline and at 1 month
Secondary Change in %CV Percentage From baseline and at 2 months
Secondary Change in %CV Percentage From baseline and at 3 months
Secondary Percentage of patients at goal %TIR Percentage 1 month
Secondary Percentage of patients at goal %TIR Percentage 2 months
Secondary Percentage of patients at goal %TIR Percentage 3 months
Secondary Percentage of patients at goal % Time Active Percentage 1 month
Secondary Percentage of patients at goal % Time Active Percentage 2 months
Secondary Percentage of patients at goal % Time Active Percentage 3 months
Secondary Percentage of patients at goal %TBR <54mg/dL Percentage 1 month
Secondary Percentage of patients at goal %TBR <54mg/dL Percentage 2 months
Secondary Percentage of patients at goal %TBR <54mg/dL Percentage 1, 2, and
Secondary Percentage of patients at goal %TBR <70mg/dL Percentage 1 month
Secondary Percentage of patients at goal %TBR <70mg/dL Percentage 2 months
Secondary Percentage of patients at goal %TBR <70mg/dL Percentage 3 months
Secondary Percentage of patients at goal %TAR >180mg/dL Percentage 1 month
Secondary Percentage of patients at goal %TAR >180mg/dL Percentage 2 months
Secondary Percentage of patients at goal %TAR >180mg/dL Percentage 3 months
Secondary Percentage of patients at goal %TAR >250mg/dL Percentage 1 month
Secondary Percentage of patients at goal %TAR >250mg/dL Percentage 2 months
Secondary Percentage of patients at goal %TAR >250mg/dL Percentage 3 months
Secondary Percentage of patients at goal % CV Percentage 1 month
Secondary Percentage of patients at goal % CV Percentage 2 months
Secondary Percentage of patients at goal % CV Percentage 3 months
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A